| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 147 | 2025 | 721 | 26.510 |
Why?
|
| Microglia | 80 | 2025 | 242 | 19.960 |
Why?
|
| Amyloid beta-Peptides | 88 | 2025 | 297 | 12.890 |
Why?
|
| Brain | 79 | 2025 | 1556 | 7.720 |
Why?
|
| Neurodegenerative Diseases | 22 | 2025 | 143 | 7.660 |
Why?
|
| Cognitive Dysfunction | 55 | 2025 | 331 | 7.630 |
Why?
|
| Inflammation | 49 | 2025 | 1148 | 6.290 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 17 | 2025 | 258 | 5.720 |
Why?
|
| Inflammasomes | 20 | 2025 | 334 | 5.570 |
Why?
|
| Amyloid beta-Protein Precursor | 27 | 2025 | 86 | 4.310 |
Why?
|
| tau Proteins | 33 | 2025 | 201 | 3.850 |
Why?
|
| Phagocytosis | 17 | 2025 | 264 | 3.760 |
Why?
|
| Animals | 156 | 2025 | 20664 | 3.660 |
Why?
|
| Biomarkers | 44 | 2025 | 1408 | 3.440 |
Why?
|
| Neurons | 20 | 2025 | 922 | 3.250 |
Why?
|
| Mice | 97 | 2025 | 10844 | 3.090 |
Why?
|
| Immunity, Innate | 14 | 2024 | 796 | 3.020 |
Why?
|
| Aging | 12 | 2024 | 745 | 2.840 |
Why?
|
| Sepsis | 9 | 2021 | 289 | 2.830 |
Why?
|
| PPAR gamma | 13 | 2014 | 76 | 2.830 |
Why?
|
| Humans | 221 | 2025 | 63465 | 2.760 |
Why?
|
| Locus Coeruleus | 12 | 2025 | 22 | 2.760 |
Why?
|
| Peptide Fragments | 28 | 2025 | 410 | 2.410 |
Why?
|
| Thiazolidinediones | 15 | 2015 | 50 | 2.360 |
Why?
|
| Mice, Transgenic | 42 | 2025 | 1277 | 2.340 |
Why?
|
| alpha-Synuclein | 3 | 2024 | 35 | 2.300 |
Why?
|
| Norepinephrine | 15 | 2019 | 102 | 2.300 |
Why?
|
| Presenilin-1 | 13 | 2025 | 61 | 2.230 |
Why?
|
| Nitric Oxide Synthase Type II | 13 | 2019 | 70 | 2.150 |
Why?
|
| Membrane Glycoproteins | 11 | 2025 | 669 | 2.080 |
Why?
|
| Disease Progression | 20 | 2025 | 1172 | 2.070 |
Why?
|
| Plaque, Amyloid | 15 | 2021 | 40 | 2.020 |
Why?
|
| Mice, Inbred C57BL | 35 | 2025 | 3396 | 2.000 |
Why?
|
| Astrocytes | 19 | 2024 | 119 | 1.970 |
Why?
|
| Hippocampus | 16 | 2024 | 270 | 1.920 |
Why?
|
| Receptors, Immunologic | 10 | 2024 | 177 | 1.780 |
Why?
|
| Nerve Degeneration | 8 | 2018 | 72 | 1.740 |
Why?
|
| Cognition Disorders | 8 | 2014 | 217 | 1.630 |
Why?
|
| Tauopathies | 5 | 2024 | 19 | 1.590 |
Why?
|
| Disease Models, Animal | 36 | 2025 | 2186 | 1.580 |
Why?
|
| Brain Diseases | 4 | 2021 | 76 | 1.560 |
Why?
|
| Nanotubes | 4 | 2025 | 24 | 1.530 |
Why?
|
| Proteomics | 3 | 2019 | 284 | 1.510 |
Why?
|
| Amyloid | 8 | 2024 | 70 | 1.480 |
Why?
|
| Encephalitis | 10 | 2011 | 35 | 1.470 |
Why?
|
| Dementia | 6 | 2024 | 260 | 1.470 |
Why?
|
| Aged | 72 | 2025 | 14443 | 1.450 |
Why?
|
| Maze Learning | 11 | 2020 | 55 | 1.440 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2025 | 2176 | 1.420 |
Why?
|
| Central Nervous System | 7 | 2024 | 197 | 1.400 |
Why?
|
| Cell Membrane Structures | 4 | 2025 | 9 | 1.400 |
Why?
|
| Cytokines | 13 | 2018 | 935 | 1.390 |
Why?
|
| Male | 93 | 2025 | 29907 | 1.380 |
Why?
|
| Synaptosomes | 3 | 2021 | 16 | 1.370 |
Why?
|
| Chitinase-3-Like Protein 1 | 3 | 2025 | 13 | 1.300 |
Why?
|
| Amyotrophic Lateral Sclerosis | 11 | 2024 | 504 | 1.290 |
Why?
|
| CARD Signaling Adaptor Proteins | 3 | 2021 | 67 | 1.230 |
Why?
|
| Female | 90 | 2025 | 32890 | 1.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 7 | 2015 | 205 | 1.180 |
Why?
|
| Glioma | 8 | 2009 | 100 | 1.150 |
Why?
|
| Cells, Cultured | 19 | 2025 | 2157 | 1.110 |
Why?
|
| Cognition | 14 | 2025 | 483 | 1.110 |
Why?
|
| Multiple Sclerosis | 4 | 2024 | 218 | 1.100 |
Why?
|
| Nervous System Diseases | 2 | 2024 | 107 | 1.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 8 | 2004 | 147 | 1.080 |
Why?
|
| Cohort Studies | 20 | 2025 | 2569 | 1.070 |
Why?
|
| Aged, 80 and over | 33 | 2025 | 5462 | 1.060 |
Why?
|
| Nitric Oxide | 6 | 2019 | 174 | 1.060 |
Why?
|
| Synapses | 3 | 2021 | 184 | 1.050 |
Why?
|
| Apolipoprotein E4 | 5 | 2024 | 46 | 1.030 |
Why?
|
| Cell Communication | 2 | 2024 | 130 | 1.020 |
Why?
|
| Leukocytes | 3 | 2024 | 103 | 1.020 |
Why?
|
| Immune System | 3 | 2024 | 130 | 0.990 |
Why?
|
| Amyloidosis | 6 | 2022 | 66 | 0.980 |
Why?
|
| Amyloid Precursor Protein Secretases | 11 | 2024 | 77 | 0.970 |
Why?
|
| Apolipoproteins E | 12 | 2024 | 109 | 0.970 |
Why?
|
| Cell Proliferation | 7 | 2025 | 988 | 0.960 |
Why?
|
| Middle Aged | 55 | 2025 | 17609 | 0.950 |
Why?
|
| Models, Biological | 6 | 2024 | 1178 | 0.940 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2025 | 52 | 0.930 |
Why?
|
| Lipopolysaccharides | 12 | 2024 | 624 | 0.930 |
Why?
|
| Proteolysis | 3 | 2021 | 145 | 0.930 |
Why?
|
| Basal Forebrain | 2 | 2022 | 4 | 0.920 |
Why?
|
| Inflammation Mediators | 7 | 2024 | 177 | 0.920 |
Why?
|
| Cerebral Cortex | 7 | 2023 | 262 | 0.910 |
Why?
|
| Neurogranin | 2 | 2024 | 11 | 0.910 |
Why?
|
| Nerve Tissue Proteins | 5 | 2021 | 424 | 0.900 |
Why?
|
| Particulate Matter | 2 | 2024 | 64 | 0.900 |
Why?
|
| Glutamine | 1 | 2025 | 47 | 0.900 |
Why?
|
| Biflavonoids | 1 | 2024 | 7 | 0.890 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2024 | 1 | 0.890 |
Why?
|
| Neuropsychological Tests | 18 | 2025 | 392 | 0.880 |
Why?
|
| Immunization, Passive | 1 | 2024 | 105 | 0.880 |
Why?
|
| Exploratory Behavior | 5 | 2017 | 37 | 0.880 |
Why?
|
| Mitochondria | 5 | 2025 | 371 | 0.880 |
Why?
|
| Neuroglia | 6 | 2024 | 79 | 0.880 |
Why?
|
| Signal Transduction | 14 | 2021 | 3036 | 0.870 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2025 | 325 | 0.870 |
Why?
|
| Flow Cytometry | 5 | 2025 | 664 | 0.860 |
Why?
|
| Hypoglycemic Agents | 6 | 2015 | 219 | 0.850 |
Why?
|
| Interleukin-1beta | 7 | 2023 | 265 | 0.850 |
Why?
|
| Long-Term Potentiation | 6 | 2020 | 43 | 0.850 |
Why?
|
| Up-Regulation | 4 | 2021 | 374 | 0.840 |
Why?
|
| Carrier Proteins | 5 | 2017 | 707 | 0.830 |
Why?
|
| Cognitive Reserve | 4 | 2024 | 8 | 0.830 |
Why?
|
| Environmental Exposure | 2 | 2024 | 218 | 0.820 |
Why?
|
| Apoptosis | 7 | 2021 | 1079 | 0.810 |
Why?
|
| Frontotemporal Dementia | 5 | 2024 | 149 | 0.810 |
Why?
|
| Toll-Like Receptor 5 | 2 | 2021 | 11 | 0.800 |
Why?
|
| Cholinergic Agents | 2 | 2023 | 9 | 0.800 |
Why?
|
| Plant Extracts | 1 | 2024 | 172 | 0.780 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 236 | 0.770 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2023 | 144 | 0.770 |
Why?
|
| Receptors, Pattern Recognition | 3 | 2024 | 36 | 0.770 |
Why?
|
| Transcription Factors | 8 | 2006 | 1513 | 0.760 |
Why?
|
| Tyrosine | 3 | 2011 | 94 | 0.760 |
Why?
|
| Sepsis-Associated Encephalopathy | 1 | 2021 | 2 | 0.740 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2021 | 5 | 0.730 |
Why?
|
| Protein Aggregation, Pathological | 2 | 2019 | 19 | 0.720 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 59 | 0.720 |
Why?
|
| Glial Fibrillary Acidic Protein | 8 | 2025 | 41 | 0.720 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 57 | 0.710 |
Why?
|
| Fatty Acid Binding Protein 3 | 1 | 2020 | 4 | 0.690 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2020 | 33 | 0.680 |
Why?
|
| Aspartic Acid Endopeptidases | 6 | 2024 | 37 | 0.680 |
Why?
|
| Ferritins | 1 | 2020 | 31 | 0.680 |
Why?
|
| Glucose | 5 | 2016 | 467 | 0.680 |
Why?
|
| Behavior, Animal | 5 | 2017 | 230 | 0.660 |
Why?
|
| Down-Regulation | 7 | 2021 | 319 | 0.660 |
Why?
|
| Central Nervous System Diseases | 3 | 2018 | 57 | 0.660 |
Why?
|
| Mice, Knockout | 13 | 2025 | 2109 | 0.650 |
Why?
|
| Memory Disorders | 6 | 2024 | 50 | 0.640 |
Why?
|
| Visual Cortex | 1 | 2019 | 26 | 0.630 |
Why?
|
| Memory | 5 | 2024 | 120 | 0.620 |
Why?
|
| Brain Neoplasms | 5 | 2009 | 308 | 0.600 |
Why?
|
| Atrophy | 8 | 2025 | 83 | 0.600 |
Why?
|
| Calgranulin B | 3 | 2021 | 6 | 0.600 |
Why?
|
| I-kappa B Proteins | 6 | 2005 | 39 | 0.600 |
Why?
|
| White Matter | 5 | 2024 | 123 | 0.590 |
Why?
|
| THP-1 Cells | 3 | 2024 | 20 | 0.580 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2018 | 3 | 0.570 |
Why?
|
| Cerebral Small Vessel Diseases | 2 | 2020 | 9 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.570 |
Why?
|
| Mitochondrial Proteins | 2 | 2018 | 102 | 0.570 |
Why?
|
| Case-Control Studies | 11 | 2023 | 1122 | 0.560 |
Why?
|
| Ceramides | 1 | 2017 | 23 | 0.550 |
Why?
|
| Rats | 17 | 2018 | 1981 | 0.550 |
Why?
|
| Longitudinal Studies | 14 | 2025 | 1256 | 0.550 |
Why?
|
| Infectious Encephalitis | 1 | 2017 | 1 | 0.540 |
Why?
|
| Positron-Emission Tomography | 12 | 2025 | 208 | 0.540 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 166 | 0.530 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 209 | 0.530 |
Why?
|
| Cell Movement | 4 | 2017 | 453 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.520 |
Why?
|
| Alarmins | 1 | 2016 | 4 | 0.520 |
Why?
|
| Models, Immunological | 1 | 2017 | 85 | 0.520 |
Why?
|
| Cell Death | 6 | 2024 | 284 | 0.520 |
Why?
|
| Mycoses | 1 | 2017 | 46 | 0.510 |
Why?
|
| Proteome | 1 | 2017 | 150 | 0.500 |
Why?
|
| Electroencephalography | 3 | 2024 | 149 | 0.490 |
Why?
|
| Virus Diseases | 1 | 2017 | 120 | 0.490 |
Why?
|
| Interferon Type I | 1 | 2017 | 187 | 0.490 |
Why?
|
| Phosphorylation | 10 | 2023 | 936 | 0.480 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2007 | 172 | 0.470 |
Why?
|
| Bacterial Infections | 1 | 2017 | 149 | 0.470 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 4 | 2021 | 59 | 0.470 |
Why?
|
| Coculture Techniques | 3 | 2025 | 96 | 0.460 |
Why?
|
| Insulysin | 2 | 2012 | 3 | 0.460 |
Why?
|
| Immunohistochemistry | 6 | 2021 | 896 | 0.460 |
Why?
|
| Germany | 7 | 2020 | 54 | 0.460 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 22 | 0.460 |
Why?
|
| Stroke | 1 | 2024 | 1196 | 0.440 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 87 | 0.440 |
Why?
|
| Acetylcholine | 2 | 2017 | 44 | 0.440 |
Why?
|
| Body Fluids | 1 | 2014 | 21 | 0.430 |
Why?
|
| Macrophages | 5 | 2024 | 1039 | 0.420 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2021 | 223 | 0.420 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2024 | 9 | 0.410 |
Why?
|
| Brain Injuries | 1 | 2015 | 140 | 0.410 |
Why?
|
| Analysis of Variance | 8 | 2015 | 609 | 0.400 |
Why?
|
| Brain Waves | 1 | 2012 | 8 | 0.400 |
Why?
|
| Reactive Oxygen Species | 3 | 2021 | 224 | 0.390 |
Why?
|
| Air Pollution | 2 | 2024 | 35 | 0.390 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2012 | 13 | 0.390 |
Why?
|
| Obesity | 3 | 2016 | 1234 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 491 | 0.380 |
Why?
|
| Neuromuscular Diseases | 1 | 2012 | 22 | 0.380 |
Why?
|
| RNA, Messenger | 15 | 2018 | 1537 | 0.380 |
Why?
|
| Monocytes | 1 | 2014 | 353 | 0.380 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 719 | 0.370 |
Why?
|
| Air Pollutants | 2 | 2024 | 93 | 0.370 |
Why?
|
| Cross-Sectional Studies | 13 | 2025 | 2576 | 0.370 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 663 | 0.360 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2011 | 6 | 0.360 |
Why?
|
| Survivors | 1 | 2012 | 171 | 0.360 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2011 | 6 | 0.360 |
Why?
|
| Cyclooxygenase 2 | 5 | 2010 | 75 | 0.350 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 20 | 0.350 |
Why?
|
| Time Factors | 7 | 2020 | 3771 | 0.350 |
Why?
|
| Endopeptidases | 3 | 2006 | 67 | 0.350 |
Why?
|
| Ibuprofen | 3 | 2006 | 17 | 0.350 |
Why?
|
| Entorhinal Cortex | 3 | 2020 | 7 | 0.350 |
Why?
|
| Receptors, Endothelin | 1 | 2010 | 1 | 0.350 |
Why?
|
| Receptors, Bradykinin | 1 | 2010 | 1 | 0.350 |
Why?
|
| Receptors, Somatostatin | 1 | 2010 | 2 | 0.340 |
Why?
|
| Olfaction Disorders | 1 | 2010 | 15 | 0.340 |
Why?
|
| Smell | 1 | 2010 | 28 | 0.340 |
Why?
|
| Mutation | 9 | 2018 | 2609 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 678 | 0.330 |
Why?
|
| Interleukin-23 | 2 | 2021 | 18 | 0.330 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 539 | 0.330 |
Why?
|
| Genetic Variation | 3 | 2019 | 383 | 0.320 |
Why?
|
| Gene Deletion | 2 | 2021 | 308 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2009 | 104 | 0.320 |
Why?
|
| Cell Survival | 5 | 2020 | 574 | 0.320 |
Why?
|
| Thiazoles | 3 | 2009 | 47 | 0.310 |
Why?
|
| Receptors, CXCR3 | 3 | 2014 | 35 | 0.310 |
Why?
|
| Adenosine Triphosphatases | 1 | 2011 | 255 | 0.310 |
Why?
|
| Tretinoin | 1 | 2009 | 50 | 0.300 |
Why?
|
| Nitric Oxide Synthase | 6 | 2005 | 47 | 0.300 |
Why?
|
| Ligands | 4 | 2019 | 416 | 0.300 |
Why?
|
| Critical Illness | 1 | 2012 | 322 | 0.300 |
Why?
|
| T-Lymphocytes | 4 | 2019 | 1008 | 0.300 |
Why?
|
| Serotonin | 1 | 2009 | 60 | 0.300 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2007 | 44 | 0.300 |
Why?
|
| Homeostasis | 3 | 2023 | 369 | 0.300 |
Why?
|
| Caspase 1 | 3 | 2021 | 111 | 0.300 |
Why?
|
| Gene Expression Regulation | 11 | 2019 | 1617 | 0.300 |
Why?
|
| Amyloidogenic Proteins | 6 | 2024 | 13 | 0.300 |
Why?
|
| Blotting, Western | 6 | 2015 | 611 | 0.300 |
Why?
|
| Protein Processing, Post-Translational | 5 | 2024 | 263 | 0.290 |
Why?
|
| Oxidative Stress | 2 | 2024 | 298 | 0.290 |
Why?
|
| Myeloid Cells | 3 | 2021 | 94 | 0.290 |
Why?
|
| Animals, Newborn | 6 | 2020 | 239 | 0.280 |
Why?
|
| Oxazoles | 2 | 2005 | 10 | 0.280 |
Why?
|
| Prospective Studies | 5 | 2024 | 3294 | 0.280 |
Why?
|
| Parkinson Disease | 3 | 2020 | 131 | 0.280 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 7 | 0.270 |
Why?
|
| Pyramidal Cells | 2 | 2024 | 26 | 0.270 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 574 | 0.270 |
Why?
|
| Netherlands | 2 | 2024 | 24 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 454 | 0.260 |
Why?
|
| Adult | 13 | 2024 | 16829 | 0.260 |
Why?
|
| Genome-Wide Association Study | 5 | 2022 | 359 | 0.260 |
Why?
|
| Gliosis | 2 | 2006 | 28 | 0.260 |
Why?
|
| Cellular Senescence | 2 | 2024 | 110 | 0.260 |
Why?
|
| Neuroprotective Agents | 3 | 2018 | 75 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 130 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 525 | 0.250 |
Why?
|
| Stress, Psychological | 1 | 2010 | 470 | 0.250 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 124 | 0.250 |
Why?
|
| bcl-2-Associated X Protein | 4 | 2009 | 48 | 0.250 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 676 | 0.250 |
Why?
|
| Cerebellar Ataxia | 2 | 2019 | 13 | 0.240 |
Why?
|
| NF-kappa B | 6 | 2021 | 469 | 0.240 |
Why?
|
| Learning | 2 | 2020 | 182 | 0.240 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 113 | 0.240 |
Why?
|
| Riluzole | 2 | 2018 | 7 | 0.240 |
Why?
|
| Demyelinating Diseases | 2 | 2017 | 16 | 0.240 |
Why?
|
| Brain Mapping | 6 | 2024 | 233 | 0.240 |
Why?
|
| Memory, Short-Term | 2 | 2020 | 60 | 0.240 |
Why?
|
| Antipsychotic Agents | 1 | 2008 | 301 | 0.240 |
Why?
|
| Genetic Association Studies | 5 | 2019 | 120 | 0.240 |
Why?
|
| Machine Learning | 2 | 2024 | 177 | 0.240 |
Why?
|
| Temporal Lobe | 3 | 2022 | 45 | 0.230 |
Why?
|
| Incretins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Diagnostic Self Evaluation | 3 | 2020 | 23 | 0.230 |
Why?
|
| Functional Laterality | 2 | 2018 | 138 | 0.230 |
Why?
|
| Cell Migration Inhibition | 1 | 2005 | 7 | 0.230 |
Why?
|
| Recovery of Function | 1 | 2007 | 288 | 0.230 |
Why?
|
| Dementia, Vascular | 1 | 2024 | 11 | 0.230 |
Why?
|
| Lewy Body Disease | 1 | 2024 | 14 | 0.230 |
Why?
|
| Neuroimmunomodulation | 1 | 2024 | 7 | 0.230 |
Why?
|
| Speech | 1 | 2025 | 63 | 0.230 |
Why?
|
| Synaptic Transmission | 3 | 2018 | 150 | 0.230 |
Why?
|
| Heterozygote | 3 | 2021 | 170 | 0.230 |
Why?
|
| DNA-Binding Proteins | 5 | 2024 | 1186 | 0.230 |
Why?
|
| Leukocyte Count | 1 | 2024 | 99 | 0.220 |
Why?
|
| Meliaceae | 1 | 2024 | 1 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 242 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 88 | 0.220 |
Why?
|
| Prodromal Symptoms | 3 | 2019 | 16 | 0.220 |
Why?
|
| Interleukin-17 | 2 | 2017 | 94 | 0.220 |
Why?
|
| Incidence | 2 | 2020 | 1377 | 0.220 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 778 | 0.220 |
Why?
|
| Cell Line, Tumor | 7 | 2009 | 1469 | 0.210 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 760 | 0.210 |
Why?
|
| Cell Line | 7 | 2019 | 2040 | 0.210 |
Why?
|
| Superoxide Dismutase | 1 | 2005 | 225 | 0.210 |
Why?
|
| Rats, Wistar | 4 | 2010 | 185 | 0.210 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 178 | 0.210 |
Why?
|
| HeLa Cells | 3 | 2021 | 536 | 0.210 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 45 | 0.210 |
Why?
|
| Frontotemporal Lobar Degeneration | 2 | 2014 | 20 | 0.210 |
Why?
|
| Epilepsy | 1 | 2024 | 113 | 0.210 |
Why?
|
| Arginase | 1 | 2023 | 6 | 0.210 |
Why?
|
| Neuroblastoma | 1 | 2003 | 52 | 0.210 |
Why?
|
| Endotoxins | 1 | 2024 | 81 | 0.210 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2003 | 78 | 0.200 |
Why?
|
| Indans | 2 | 2024 | 12 | 0.200 |
Why?
|
| Protein Folding | 2 | 2015 | 267 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2018 | 619 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2021 | 687 | 0.200 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2022 | 19 | 0.190 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2022 | 4 | 0.190 |
Why?
|
| Prostaglandin D2 | 1 | 2002 | 4 | 0.190 |
Why?
|
| Status Epilepticus | 1 | 2022 | 24 | 0.190 |
Why?
|
| Membrane Proteins | 4 | 2021 | 894 | 0.190 |
Why?
|
| Dizziness | 1 | 2022 | 18 | 0.190 |
Why?
|
| Benzylamines | 4 | 2010 | 30 | 0.190 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2017 | 47 | 0.190 |
Why?
|
| Gene Expression | 3 | 2008 | 840 | 0.190 |
Why?
|
| In Vitro Techniques | 3 | 2015 | 490 | 0.190 |
Why?
|
| Gray Matter | 2 | 2024 | 35 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 456 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 863 | 0.180 |
Why?
|
| CD36 Antigens | 1 | 2021 | 26 | 0.180 |
Why?
|
| HEK293 Cells | 2 | 2021 | 622 | 0.180 |
Why?
|
| Protein Aggregates | 1 | 2021 | 20 | 0.180 |
Why?
|
| Seizures | 2 | 2022 | 143 | 0.180 |
Why?
|
| Nerve Net | 2 | 2023 | 97 | 0.180 |
Why?
|
| Protein Array Analysis | 1 | 2021 | 26 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2023 | 321 | 0.180 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 26 | 0.180 |
Why?
|
| Autophagy | 1 | 2023 | 225 | 0.170 |
Why?
|
| Salmonella | 1 | 2021 | 44 | 0.170 |
Why?
|
| Blood-Brain Barrier | 4 | 2023 | 85 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 32 | 0.170 |
Why?
|
| Cytoskeleton | 1 | 2021 | 139 | 0.170 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2014 | 10 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 131 | 0.170 |
Why?
|
| Microscopy, Confocal | 2 | 2019 | 235 | 0.170 |
Why?
|
| Spatial Learning | 1 | 2020 | 2 | 0.170 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2020 | 6 | 0.170 |
Why?
|
| Spatial Navigation | 1 | 2020 | 7 | 0.170 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2018 | 115 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2021 | 53 | 0.170 |
Why?
|
| Phospholipase C gamma | 1 | 2020 | 9 | 0.170 |
Why?
|
| Europe | 5 | 2020 | 195 | 0.160 |
Why?
|
| Radionuclide Imaging | 2 | 2010 | 125 | 0.160 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2021 | 143 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 121 | 0.160 |
Why?
|
| Research | 1 | 2021 | 193 | 0.160 |
Why?
|
| Actins | 1 | 2021 | 259 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2019 | 9 | 0.160 |
Why?
|
| Executive Function | 1 | 2020 | 65 | 0.160 |
Why?
|
| CD11b Antigen | 4 | 2012 | 19 | 0.160 |
Why?
|
| Pyroptosis | 1 | 2020 | 32 | 0.160 |
Why?
|
| Oligopeptides | 1 | 2020 | 132 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 790 | 0.160 |
Why?
|
| Immunoprecipitation | 3 | 2024 | 126 | 0.160 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2019 | 12 | 0.160 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 2011 | 7 | 0.160 |
Why?
|
| Wakefulness | 1 | 2019 | 43 | 0.160 |
Why?
|
| Pattern Recognition, Visual | 1 | 2019 | 40 | 0.150 |
Why?
|
| Protein Biosynthesis | 2 | 2021 | 319 | 0.150 |
Why?
|
| Peroxynitrous Acid | 2 | 2011 | 5 | 0.150 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 95 | 0.150 |
Why?
|
| Protein Interaction Maps | 1 | 2019 | 35 | 0.150 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 35 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2019 | 39 | 0.150 |
Why?
|
| Language | 1 | 2020 | 150 | 0.150 |
Why?
|
| NF-KappaB Inhibitor alpha | 5 | 2005 | 27 | 0.150 |
Why?
|
| Acetamides | 1 | 2018 | 13 | 0.150 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 46 | 0.150 |
Why?
|
| Cuprizone | 2 | 2017 | 3 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 344 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 152 | 0.140 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 2012 | 35 | 0.140 |
Why?
|
| Interleukin-18 | 1 | 2018 | 74 | 0.140 |
Why?
|
| Piperidines | 1 | 2018 | 63 | 0.140 |
Why?
|
| Interleukin-1 | 3 | 2003 | 156 | 0.140 |
Why?
|
| Neuronal Plasticity | 1 | 2019 | 150 | 0.140 |
Why?
|
| Spatial Memory | 1 | 2017 | 8 | 0.140 |
Why?
|
| Transcriptome | 1 | 2021 | 388 | 0.140 |
Why?
|
| Bromodeoxyuridine | 2 | 2009 | 43 | 0.140 |
Why?
|
| Rest | 1 | 2018 | 46 | 0.140 |
Why?
|
| Frontal Lobe | 1 | 2018 | 64 | 0.140 |
Why?
|
| Visual Perception | 1 | 2017 | 41 | 0.140 |
Why?
|
| Chemokines | 2 | 2010 | 93 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 215 | 0.140 |
Why?
|
| Cerebrum | 1 | 2017 | 16 | 0.140 |
Why?
|
| Police | 1 | 2017 | 39 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 3 | 2003 | 227 | 0.140 |
Why?
|
| Caspase 3 | 2 | 2009 | 108 | 0.140 |
Why?
|
| Ephrin-B2 | 1 | 2017 | 4 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 40 | 0.140 |
Why?
|
| Acetylcholinesterase | 1 | 2017 | 15 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 131 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 2 | 2009 | 278 | 0.130 |
Why?
|
| Protein Domains | 1 | 2017 | 149 | 0.130 |
Why?
|
| Antibodies | 1 | 2017 | 183 | 0.130 |
Why?
|
| Myelin Sheath | 1 | 2017 | 37 | 0.130 |
Why?
|
| Locomotion | 1 | 2017 | 116 | 0.130 |
Why?
|
| Complement System Proteins | 1 | 2017 | 105 | 0.130 |
Why?
|
| Granulocytes | 1 | 2017 | 71 | 0.130 |
Why?
|
| Age Factors | 3 | 2020 | 1559 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2017 | 90 | 0.130 |
Why?
|
| Risk Factors | 3 | 2021 | 5356 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 2 | 2008 | 181 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 542 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2017 | 200 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 213 | 0.130 |
Why?
|
| beta-Cyclodextrins | 1 | 2016 | 21 | 0.120 |
Why?
|
| Drug Synergism | 2 | 2009 | 142 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 301 | 0.120 |
Why?
|
| Genetic Therapy | 3 | 2007 | 791 | 0.120 |
Why?
|
| Liver X Receptors | 2 | 2016 | 8 | 0.120 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2015 | 1 | 0.120 |
Why?
|
| Neurogenesis | 1 | 2016 | 64 | 0.120 |
Why?
|
| Cytoplasm | 1 | 2017 | 275 | 0.120 |
Why?
|
| Breath Tests | 1 | 2015 | 14 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1553 | 0.120 |
Why?
|
| Protective Factors | 1 | 2015 | 33 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 431 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 3 | 2020 | 82 | 0.120 |
Why?
|
| Phospholipase D | 1 | 2015 | 6 | 0.120 |
Why?
|
| Nootropic Agents | 1 | 2015 | 13 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2010 | 878 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 671 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 175 | 0.110 |
Why?
|
| Ethanol | 1 | 2018 | 321 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 596 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2006 | 369 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 462 | 0.110 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2014 | 2 | 0.110 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2014 | 3 | 0.110 |
Why?
|
| Immunization | 1 | 2015 | 133 | 0.110 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2014 | 1 | 0.110 |
Why?
|
| Reactive Nitrogen Species | 1 | 2014 | 8 | 0.110 |
Why?
|
| Alleles | 4 | 2019 | 448 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 771 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2016 | 153 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 429 | 0.110 |
Why?
|
| HLA-DQ Antigens | 1 | 2014 | 14 | 0.110 |
Why?
|
| Neprilysin | 2 | 2012 | 9 | 0.110 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2005 | 31 | 0.110 |
Why?
|
| Cholesterol | 3 | 2016 | 259 | 0.110 |
Why?
|
| Metformin | 1 | 2015 | 73 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2005 | 373 | 0.110 |
Why?
|
| Phenotype | 4 | 2021 | 1207 | 0.110 |
Why?
|
| COS Cells | 1 | 2014 | 175 | 0.110 |
Why?
|
| Esophageal Achalasia | 1 | 2014 | 37 | 0.110 |
Why?
|
| Neoplasms | 1 | 2004 | 1364 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 730 | 0.100 |
Why?
|
| Guanylate Cyclase | 2 | 2003 | 10 | 0.100 |
Why?
|
| Endotoxemia | 1 | 2013 | 11 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2017 | 381 | 0.100 |
Why?
|
| Anxiety | 3 | 2023 | 425 | 0.100 |
Why?
|
| Calgranulin A | 1 | 2012 | 5 | 0.100 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 60 | 0.100 |
Why?
|
| Microvessels | 1 | 2013 | 19 | 0.100 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2003 | 33 | 0.100 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 2 | 2010 | 3 | 0.100 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2025 | 19 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2018 | 5686 | 0.100 |
Why?
|
| Observation | 1 | 2012 | 30 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 4 | 2023 | 367 | 0.100 |
Why?
|
| Neural Conduction | 1 | 2012 | 31 | 0.100 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2012 | 33 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2013 | 55 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 5 | 2007 | 456 | 0.100 |
Why?
|
| Peripheral Nerves | 1 | 2012 | 34 | 0.090 |
Why?
|
| Electromyography | 1 | 2012 | 96 | 0.090 |
Why?
|
| Neurogenic Inflammation | 1 | 2011 | 1 | 0.090 |
Why?
|
| Depression | 2 | 2023 | 894 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2012 | 107 | 0.090 |
Why?
|
| Cell Division | 2 | 2003 | 450 | 0.090 |
Why?
|
| Biophysics | 1 | 2011 | 42 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2020 | 6660 | 0.090 |
Why?
|
| Models, Neurological | 2 | 2009 | 80 | 0.090 |
Why?
|
| Copper-transporting ATPases | 1 | 2011 | 7 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 429 | 0.090 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 130 | 0.090 |
Why?
|
| Insulin | 1 | 2015 | 686 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 51 | 0.090 |
Why?
|
| Eye Diseases | 1 | 2011 | 36 | 0.090 |
Why?
|
| Electric Stimulation | 1 | 2011 | 139 | 0.090 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2011 | 11 | 0.090 |
Why?
|
| Denervation | 2 | 2009 | 18 | 0.090 |
Why?
|
| Hand Strength | 1 | 2011 | 35 | 0.090 |
Why?
|
| Quality Control | 1 | 2011 | 74 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 165 | 0.090 |
Why?
|
| Protein Denaturation | 1 | 2011 | 67 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2011 | 128 | 0.090 |
Why?
|
| Milk | 1 | 2011 | 42 | 0.090 |
Why?
|
| Quality of Life | 2 | 2022 | 1228 | 0.090 |
Why?
|
| Brain Chemistry | 2 | 2019 | 76 | 0.090 |
Why?
|
| Immunoassay | 1 | 2011 | 70 | 0.090 |
Why?
|
| Ki-67 Antigen | 2 | 2011 | 37 | 0.090 |
Why?
|
| Extracellular Space | 1 | 2010 | 28 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 435 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 291 | 0.080 |
Why?
|
| Copper | 1 | 2011 | 51 | 0.080 |
Why?
|
| Chromogranin A | 1 | 2010 | 7 | 0.080 |
Why?
|
| Thymidine Kinase | 2 | 2007 | 18 | 0.080 |
Why?
|
| Transfection | 2 | 2009 | 694 | 0.080 |
Why?
|
| Neurofibrillary Tangles | 1 | 2010 | 11 | 0.080 |
Why?
|
| Restraint, Physical | 1 | 2010 | 40 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 137 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2011 | 127 | 0.080 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2010 | 20 | 0.080 |
Why?
|
| Prevalence | 3 | 2022 | 1380 | 0.080 |
Why?
|
| Exosomes | 1 | 2010 | 48 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2010 | 43 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 702 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2011 | 158 | 0.080 |
Why?
|
| Memory, Episodic | 2 | 2024 | 20 | 0.080 |
Why?
|
| Amino Acids | 1 | 2010 | 147 | 0.080 |
Why?
|
| Retinoid X Receptor gamma | 1 | 2009 | 1 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 17 | 0.080 |
Why?
|
| Tetrazolium Salts | 1 | 2009 | 15 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 109 | 0.080 |
Why?
|
| Annexin A5 | 1 | 2009 | 21 | 0.080 |
Why?
|
| Cell Count | 2 | 2016 | 132 | 0.080 |
Why?
|
| Cytochromes c | 1 | 2009 | 29 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 16 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2018 | 289 | 0.080 |
Why?
|
| Afferent Pathways | 1 | 2009 | 18 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2012 | 407 | 0.080 |
Why?
|
| ROC Curve | 2 | 2024 | 282 | 0.080 |
Why?
|
| Arousal | 1 | 2009 | 42 | 0.080 |
Why?
|
| Presynaptic Terminals | 1 | 2009 | 37 | 0.080 |
Why?
|
| Receptors, LDL | 1 | 2008 | 34 | 0.070 |
Why?
|
| Schizophrenia | 1 | 2011 | 265 | 0.070 |
Why?
|
| Critical Care | 1 | 2012 | 397 | 0.070 |
Why?
|
| Membrane Lipids | 1 | 2008 | 28 | 0.070 |
Why?
|
| Axons | 1 | 2009 | 123 | 0.070 |
Why?
|
| Motor Activity | 1 | 2011 | 346 | 0.070 |
Why?
|
| Lipoproteins | 1 | 2008 | 84 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 112 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 199 | 0.070 |
Why?
|
| Neurites | 2 | 2019 | 23 | 0.070 |
Why?
|
| ADAM10 Protein | 2 | 2019 | 11 | 0.070 |
Why?
|
| Adolescent | 2 | 2012 | 6253 | 0.070 |
Why?
|
| Cerebellum | 3 | 2003 | 95 | 0.070 |
Why?
|
| Biological Transport | 3 | 2016 | 291 | 0.070 |
Why?
|
| Hypertension | 1 | 2013 | 585 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2019 | 661 | 0.070 |
Why?
|
| Age of Onset | 2 | 2021 | 174 | 0.070 |
Why?
|
| Mice, Inbred C3H | 2 | 2019 | 176 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2010 | 150 | 0.070 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2007 | 22 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 19 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2008 | 250 | 0.070 |
Why?
|
| Proteins | 1 | 2013 | 750 | 0.070 |
Why?
|
| Neuropeptides | 2 | 2018 | 82 | 0.070 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2006 | 3 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2006 | 81 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2007 | 86 | 0.060 |
Why?
|
| Housing, Animal | 1 | 2006 | 15 | 0.060 |
Why?
|
| Liver | 1 | 2011 | 855 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 58 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2006 | 69 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 1653 | 0.060 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2006 | 7 | 0.060 |
Why?
|
| Vesicular Acetylcholine Transport Proteins | 1 | 2006 | 1 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 615 | 0.060 |
Why?
|
| Spain | 2 | 2018 | 33 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 61 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 78 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2006 | 21 | 0.060 |
Why?
|
| Pharmacoepidemiology | 1 | 2006 | 7 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 37 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2003 | 140 | 0.060 |
Why?
|
| Ectodysplasins | 1 | 2005 | 2 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2006 | 27 | 0.060 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cyclic GMP | 2 | 2003 | 31 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 48 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2005 | 26 | 0.060 |
Why?
|
| Memantine | 1 | 2006 | 23 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2006 | 87 | 0.060 |
Why?
|
| Jurkat Cells | 1 | 2005 | 110 | 0.060 |
Why?
|
| Glycosphingolipids | 1 | 2005 | 9 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2007 | 144 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2024 | 1008 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 13 | 0.060 |
Why?
|
| Cadherins | 2 | 2003 | 80 | 0.060 |
Why?
|
| Estrogens | 1 | 2006 | 116 | 0.060 |
Why?
|
| Isoaspartic Acid | 1 | 2024 | 1 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2017 | 240 | 0.060 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2024 | 4 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2024 | 78 | 0.050 |
Why?
|
| Protein Transport | 2 | 2019 | 401 | 0.050 |
Why?
|
| MPTP Poisoning | 1 | 2004 | 1 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2007 | 879 | 0.050 |
Why?
|
| Autonomic Pathways | 1 | 2003 | 2 | 0.050 |
Why?
|
| Antioxidants | 1 | 2006 | 252 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 216 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2024 | 197 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 739 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2003 | 20 | 0.050 |
Why?
|
| Personality | 1 | 2023 | 29 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 236 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2006 | 255 | 0.050 |
Why?
|
| Haplotypes | 2 | 2014 | 131 | 0.050 |
Why?
|
| Lung | 2 | 2021 | 956 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2003 | 21 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2003 | 36 | 0.050 |
Why?
|
| Serine | 1 | 2023 | 91 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2024 | 118 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2024 | 265 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 45 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2007 | 419 | 0.050 |
Why?
|
| Kainic Acid | 1 | 2022 | 8 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 122 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 166 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2003 | 80 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2007 | 277 | 0.050 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2002 | 9 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 10 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 35 | 0.050 |
Why?
|
| Neural Pathways | 1 | 2023 | 99 | 0.050 |
Why?
|
| Parietal Lobe | 1 | 2022 | 28 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2022 | 53 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 21 | 0.050 |
Why?
|
| Rifabutin | 1 | 2002 | 3 | 0.050 |
Why?
|
| Sweden | 2 | 2013 | 58 | 0.050 |
Why?
|
| Young Adult | 1 | 2012 | 4695 | 0.050 |
Why?
|
| Remission Induction | 1 | 2002 | 148 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 98 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2002 | 34 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 98 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 2462 | 0.050 |
Why?
|
| beta-Synuclein | 1 | 2021 | 1 | 0.050 |
Why?
|
| GAP-43 Protein | 1 | 2021 | 2 | 0.050 |
Why?
|
| Aquaporin 4 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 42 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2002 | 137 | 0.040 |
Why?
|
| Somatosensory Cortex | 1 | 2021 | 20 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 27 | 0.040 |
Why?
|
| Neurofilament Proteins | 1 | 2021 | 21 | 0.040 |
Why?
|
| Survival | 1 | 2021 | 11 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 99 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2021 | 5 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2002 | 204 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1148 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 1603 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2021 | 16 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2002 | 187 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2021 | 204 | 0.040 |
Why?
|
| DNA | 1 | 2005 | 837 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2021 | 209 | 0.040 |
Why?
|
| Language Tests | 1 | 2020 | 39 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2014 | 190 | 0.040 |
Why?
|
| Herpesvirus 7, Human | 1 | 2020 | 2 | 0.040 |
Why?
|
| Porphyromonas gingivalis | 1 | 2020 | 17 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2021 | 153 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 97 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2020 | 21 | 0.040 |
Why?
|
| Alum Compounds | 1 | 2019 | 3 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 2020 | 17 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 220 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 393 | 0.040 |
Why?
|
| Interferon-gamma | 3 | 2011 | 567 | 0.040 |
Why?
|
| Solubility | 3 | 2006 | 180 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 153 | 0.040 |
Why?
|
| Healthy Aging | 1 | 2019 | 8 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2019 | 114 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2019 | 39 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2019 | 84 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 337 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 1124 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 193 | 0.040 |
Why?
|
| Neurology | 1 | 2019 | 41 | 0.040 |
Why?
|
| Limbic System | 1 | 2019 | 27 | 0.040 |
Why?
|
| Borrelia burgdorferi | 1 | 2020 | 90 | 0.040 |
Why?
|
| Piracetam | 1 | 2018 | 8 | 0.040 |
Why?
|
| Dendritic Spines | 1 | 2018 | 11 | 0.040 |
Why?
|
| Caregivers | 1 | 2021 | 272 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2019 | 74 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 696 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 21 | 0.040 |
Why?
|
| Presenilin-2 | 1 | 2018 | 20 | 0.040 |
Why?
|
| Amnesia | 1 | 2018 | 9 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2018 | 118 | 0.040 |
Why?
|
| Biotinylation | 2 | 2009 | 36 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 921 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2018 | 251 | 0.030 |
Why?
|
| Receptor, EphB1 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2017 | 9 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2017 | 13 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 99 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 363 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 980 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2016 | 13 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 117 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2016 | 6 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2017 | 157 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 2016 | 24 | 0.030 |
Why?
|
| Endocytosis | 2 | 2008 | 152 | 0.030 |
Why?
|
| Oxygen | 1 | 2018 | 317 | 0.030 |
Why?
|
| Crystallization | 1 | 2016 | 99 | 0.030 |
Why?
|
| Huntington Disease | 1 | 2017 | 154 | 0.030 |
Why?
|
| Family | 1 | 2018 | 238 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 1331 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1094 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 672 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 187 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2015 | 51 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 32 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 270 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1748 | 0.030 |
Why?
|
| Stem Cells | 1 | 2017 | 259 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2014 | 56 | 0.030 |
Why?
|
| RNA Interference | 1 | 2018 | 618 | 0.030 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2014 | 14 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 574 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 47 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 114 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 866 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2015 | 158 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 753 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2081 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 90 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 77 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 197 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 87 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2013 | 23 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 642 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Finland | 1 | 2013 | 20 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 347 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 415 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 379 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 135 | 0.020 |
Why?
|
| DNA Repeat Expansion | 1 | 2013 | 58 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2012 | 12 | 0.020 |
Why?
|
| Protein Subunits | 2 | 2003 | 166 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2012 | 33 | 0.020 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2011 | 22 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 242 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2011 | 8 | 0.020 |
Why?
|
| C9orf72 Protein | 1 | 2013 | 114 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2011 | 37 | 0.020 |
Why?
|
| Microdissection | 1 | 2011 | 7 | 0.020 |
Why?
|
| Endophthalmitis | 1 | 2011 | 12 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 33 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Poly I-C | 1 | 2011 | 76 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2679 | 0.020 |
Why?
|
| Blindness | 1 | 2011 | 41 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 58 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 139 | 0.020 |
Why?
|
| Biological Assay | 1 | 2011 | 58 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 356 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 92 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 464 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1277 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 111 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1149 | 0.020 |
Why?
|
| Propanolamines | 1 | 2010 | 10 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 852 | 0.020 |
Why?
|
| Cricetulus | 1 | 2009 | 99 | 0.020 |
Why?
|
| Imidazoles | 1 | 2010 | 82 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 883 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2009 | 86 | 0.020 |
Why?
|
| CHO Cells | 1 | 2009 | 189 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 665 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1991 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 367 | 0.020 |
Why?
|
| Lanosterol | 1 | 2008 | 4 | 0.020 |
Why?
|
| Drosophila | 1 | 2011 | 433 | 0.020 |
Why?
|
| Raclopride | 1 | 2007 | 2 | 0.020 |
Why?
|
| Rats, Nude | 1 | 2007 | 25 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Dideoxynucleosides | 1 | 2007 | 9 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 34 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 72 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2006 | 36 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 257 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2006 | 65 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 189 | 0.020 |
Why?
|
| Rhodamines | 1 | 2005 | 20 | 0.010 |
Why?
|
| Gangliosides | 1 | 2005 | 18 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2005 | 44 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 2005 | 64 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2006 | 189 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 411 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 2337 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 296 | 0.010 |
Why?
|
| Cerebellar Nuclei | 1 | 2003 | 4 | 0.010 |
Why?
|
| Enzyme Stability | 1 | 2003 | 46 | 0.010 |
Why?
|
| Half-Life | 1 | 2003 | 80 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2005 | 219 | 0.010 |
Why?
|
| Vinculin | 1 | 2003 | 3 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 2003 | 15 | 0.010 |
Why?
|
| Interferon beta-1a | 1 | 2003 | 9 | 0.010 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2003 | 33 | 0.010 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2002 | 1 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 496 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 5 | 0.010 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2002 | 21 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2002 | 14 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 23 | 0.010 |
Why?
|
| Nitrites | 1 | 2002 | 11 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 44 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 92 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 209 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 217 | 0.010 |
Why?
|
| Quinones | 1 | 2002 | 5 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2002 | 14 | 0.010 |
Why?
|
| Quercetin | 1 | 2002 | 27 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 2002 | 25 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 36 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 93 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 293 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 574 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 125 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 1998 | 0.010 |
Why?
|